E - Glenmark

More documents

Recommendations

Info

Overview: Build/consolidate “branded generic” marketing footprint: Emphasis on the top 15 RoW countries RoW accounts ~12% of Global Pharma Market… …but 15 country markets contribute ~ 90% of ROW Market (2005 sales in $ Bn) 265 $ 21 bn Acquire • Africa: Egypt • AsiaPac/ME: China, Indonesia 170 6 60 64 90% $ 16 bn $ 27 bn Enter or Ally Grow • AsiaPac/ME: Australia, Saudi Arabia, S Korea • Africa: SA, Nigeria • Lat Am: Brazil, Argentina • AsiaPac/ME: Philippines, India, S Lanka, Malaysia, Russia US EU Japan ROW These 15 country markets are jointly growing at an annual rate of over 15% that will put them at 20% of the Global Pharma market by 2012
Overview: Acquire branded generic footprint in EU; market generics in the US market through own front-end EU Market US Market • Focus on select branded generic markets: Spain, Italy, Central and Eastern European Countries • Acquire privately held front ends – Euro 8-12 Mn Sales, cash generating – Pipeline in place for next 2-3 years – Good local brand equity – High overlap in prescriber base with our research focus • File and launch branded generics through own front-ends; also provide dossiers to partners for non-core markets • Partner with players to fund high cost developments – share marketing rights • Remain focused on generics • Market products to distributors, chains, wholesalers through own front-end • Combination of Make/Partner/Buy to build depth of portfolio rapidly – Own development – Product development alliances – Acquire registrations – Licensing marketing rights • Focus own development on specific niches with greater margins/sustainability: Dermatology and controlled substances • Use own API for cost advantage
Page 2 and 3: Disclaimer This presentation has be
Page 4 and 5: Background History Identity / Scope
Page 6 and 7: Strategic roadmap: Transform into a
Page 8 and 9: Build proprietary pipeline of NCEs/
Page 10 and 11: NCE Research & Development Plan to
Page 12 and 13: NCE Pipeline Lead Target Indication
Page 14 and 15: Biologics research in Switzerland i
Page 18 and 19: India Formulations Current Status:
Page 20 and 21: India Formulations Moving forward,
Page 22 and 23: Latin America Status in FY 2006 Ac
Page 24 and 25: USA - Generic Formulations Progress
Page 26 and 27: Europe / UK - Start-up phase Strate
Page 28 and 29: Active Pharmaceutical Ingredients S
Page 30 and 31: Financials and Projections Performa
Page 32 and 33: Summary
Page 34: Thank you

E - Glenmark

Create successful ePaper yourself

Delete template?

Save as template?